$1.15
+0.04 (+3.60%)
Open$1.12
Previous Close$1.11
Day High$1.15
Day Low$1.10
52W High$7.60
52W Low$1.07
Volume—
Avg Volume1.04M
Market Cap105.21M
P/E Ratio—
EPS$-0.15
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,495.7% upside
Current
$1.15
$1.15
Target
$29.85
$29.85
$17.55
$29.85 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 62.53M | 56.87M | 56.55M |
| Net Income | 10.24M | 9.50M | 10.72M |
| Profit Margin | 16.4% | 16.7% | 19.0% |
| EBITDA | 18.97M | 15.63M | 16.61M |
| Free Cash Flow | 7.70M | 5.60M | 6.46M |
| Rev Growth | +23.0% | -7.3% | -7.0% |
| Debt/Equity | 0.80 | 0.99 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |